Evidence map›Paper›PMID 41272750›Full record

ArticleTrials2025

Ivabradine for prevention of myocardial injury after noncardiac surgery (PREVENT-MINS trial): study protocol for a randomized controlled trial.

Wojciech Szczeklik, Jakub Fronczek, Zbigniew Putowski, Anna Włudarczyk, Jacek Górka, Bożena Seczyńska, Dominika Gryszówka, Agnieszka Widawska, Szymon Białka, Piotr Palaczyński and 28 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05279651 (Ivabradine for PREVENTion of Myocardial Injury After Noncardiac Surgery), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05279651 phase3active not recruitingnot on this map

Ivabradine for PREVENTion of Myocardial Injury After Noncardiac Surgery

TypeinterventionalSponsorJagiellonian UniversityRan2022 to 2026Enrolled2,146ConditionsMyocardial Injury After Noncardiac Surgery (MINS), Myocardial IschemiaArmsIvabradine, Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Wojciech SzczeklikCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland. wojciech.szczeklik@uj.edu.pl.ORCID http://orcid.org/0000-0002-1349-1123
Jakub FronczekCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Zbigniew PutowskiCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Anna WłudarczykCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Jacek GórkaCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Bożena SeczyńskaCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Dominika GryszówkaJagiellonian Center for Clinical Trials, Jagiellonian University Medical College, Krakow, Poland.
Agnieszka WidawskaJagiellonian Center for Clinical Trials, Jagiellonian University Medical College, Krakow, Poland.
Szymon BiałkaDepartment of Anesthesiology and Intensive Care, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Piotr PalaczyńskiDepartment of Anesthesiology and Intensive Care, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland.
Michał BorysInstitute of Medical Sciences, Faculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Poland.
Paweł KutnikInstitute of Medical Sciences, Faculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Poland.
Tomasz CzarnikDepartment of Anaesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland.
Tomasz KrólickiDepartment of Anaesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland.
Anna SzczepańskaDepartment of Anaesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland.
Norbert HajderDepartment of Anaesthesiology and Intensive Care, Medical University of Silesia, Katowice, Poland.
Marcin MożańskiDepartment of Anesthesiology and Intensive Care, Military Institute of Medicine-National Research Institute, Warsaw, Poland.
Dariusz OnichimowskiDepartment of Anaesthesiology and Intensive Care, Faculty of Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland.
Katarzyna KotfisDepartment of Anesthesiology, Intensive Care and Pain Management, Pomeranian Medical University, Szczecin, Poland.
Janusz Trzebicki1 st Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Łukasz SadowskiDepartment of Anaesthesiology and Intensive Therapy, Central Teaching Hospital of the Medical University of Łódź, Łódź, Poland.
Joanna Sołek-PastuszkaDepartment of Anaesthesiology and Intensive Therapy, Pomeranian Medical University, Szczecin, Poland.
Paweł GrudzieńDepartment of Anaesthesiology and Intensive Therapy, E. Szczeklik Specialist Hospital in Tarnów, Tarnów, Poland.
Wojciech MudynaDepartment of Anaesthesiology and Intensive Therapy, Ludwik Rydygier Memorial Specialist Hospital in Krakow, Krakow, Poland.
Agnieszka Misiewska-KaczurDepartment of Anesthesiology and Intensive Care, Silesian Hospital in Cieszyn, Cieszyn, Poland.
Radosław OwczukDepartment of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Bartosz KudlińskiDepartment of Anesthetics, Intensive Care and Emergency Medicine, Collegium Medicum, University of Zielona Góra, Zielona Góra, Poland.
Dorota StudzińskaCentre for Intensive Care and Perioperative Medicine, Jagiellonian University Medical College, Krakow, Poland.
Jarosław PawlikFaculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.
Adam Makowski2nd Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Warsaw, Poland.
Mirosław Ziętkiewicz2nd Department of Anaesthesiology and Intensive Care, John Paul II Hospital in Krakow, Krakow, Poland.
Mikołaj PrzydaczDepartment of Urology, Jagiellonian University Medical College, Krakow, Poland.
Waldemar GoździkClinical Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Wroclaw, Poland.
Wojciech GolaCollegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland.
Przemysław JasiewiczDepartment of Anesthesiology and Intensive Care, Collegium Medicum, Nicolaus Copernicus University, Toruń, Poland.
Zhiguo ZhaoDepartment of Biostatistics and Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
Yu ShyrDepartment of Biostatistics and Center for Quantitative Sciences, Vanderbilt University School of Medicine, Nashville, TN, USA.
P J DevereauxDepartment of Medicine, McMaster University, Hamilton, ON, Canada.

Funding

Agencja Badań Medycznych 2019/ABM/01/00019
6 · The paper itself

Abstract

backgroundMyocardial injury is a major cause of death after noncardiac surgery and is associated with long-term cardiovascular outcomes. Perioperative tachycardia increases this risk. Although perioperative beta blockers prevent myocardial injury, they increase the risk of death and stroke, which analyses suggest is due to a significant increase in hypotension. Ivabradine, a selective heart rate-lowering drug, may offer a safer alternative. The primary objective of the PREVENT-MINS trial is to determine whether perioperative administration of ivabradine is superior to placebo for the prevention of myocardial injury after noncardiac surgery (MINS) in patients with or at risk of atherosclerotic disease having noncardiac surgery. 

methodsThe PREVENT-MINS trial is a multicentre, parallel-group, blinded, placebo-controlled trial conducted in 26 hospitals in Poland. It will enroll 2500 patients aged ≥ 45 years undergoing noncardiac surgery with at least one risk factor for myocardial injury. Participants will be randomized in a 1:1 ratio to receive ivabradine 5 mg orally twice daily for 7 days starting 1 h before surgery or placebo. The primary outcome is MINS within 30 days after randomization; independent experts will adjudicate this outcome. Secondary outcomes include vascular complications, mortality, haemodynamics, and quality of life at 30 days. Additional tertiary and 1-year outcomes will assess long-term cardiovascular and surgical complications. Analyses will follow an intention-to-treat approach. For the primary outcome, a chi-squared test will be conducted, with results presented as unadjusted relative risk (RR) accompanied by 95% confidence intervals (CIs) and p-values.  DISCUSSION: This trial will generate high-quality, generalizable data due to its large population and rigorous design, including blinding. Moreover, it will be one of the first large-scale trials specifically focused on preventing MINS.

trial registrationClinicalTrials.gov NCT05279651. Registered on 4 March 2022.

Indexed as

Cardiovascular AgentsIvabradinePostoperative ComplicationsSurgical Procedures, OperativeFemaleHumansMiddle AgedMulticenter Studies as TopicPolandRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeCardiovascular AgentsIvabradineIvabradineMyocardial injury after noncardiac surgeryPerioperative care

Identifiers

PMID41272750
PMCPMC12639926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.